Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report)'s stock price was down 5.8% on Tuesday . The stock traded as low as $15.36 and last traded at $15.40. Approximately 1,366,835 shares changed hands during trading, a decline of 15% from the average daily volume of 1,607,717 shares. The stock had previously closed at $16.34.
Analyst Upgrades and Downgrades
Several research analysts recently weighed in on NTLA shares. Chardan Capital dropped their price target on Intellia Therapeutics from $94.00 to $88.00 and set a "buy" rating on the stock in a research report on Thursday, October 24th. Citigroup dropped their price target on Intellia Therapeutics from $25.00 to $19.00 and set a "neutral" rating on the stock in a research report on Friday. Stifel Nicolaus dropped their price target on Intellia Therapeutics from $80.00 to $64.00 and set a "buy" rating on the stock in a research report on Wednesday, September 11th. Evercore ISI raised Intellia Therapeutics to a "strong-buy" rating in a research report on Friday, August 9th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $54.00 target price on shares of Intellia Therapeutics in a research report on Thursday, September 19th. One analyst has rated the stock with a sell rating, five have issued a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $59.13.
Get Our Latest Report on NTLA
Intellia Therapeutics Price Performance
The company has a market capitalization of $1.52 billion, a price-to-earnings ratio of -2.74 and a beta of 1.76. The firm has a 50-day moving average price of $20.57 and a two-hundred day moving average price of $22.65.
Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.29). The firm had revenue of $7.00 million during the quarter, compared to the consensus estimate of $19.68 million. During the same period in the prior year, the company earned ($1.40) earnings per share. Intellia Therapeutics's revenue for the quarter was down 48.5% compared to the same quarter last year. On average, equities analysts predict that Intellia Therapeutics, Inc. will post -5.22 EPS for the current year.
Insider Buying and Selling at Intellia Therapeutics
In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,012 shares of the company's stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total value of $38,248.12. Following the sale, the chief accounting officer now owns 47,012 shares in the company, valued at $893,698.12. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 3.20% of the company's stock.
Hedge Funds Weigh In On Intellia Therapeutics
A number of large investors have recently made changes to their positions in NTLA. Vanguard Group Inc. increased its stake in shares of Intellia Therapeutics by 8.9% during the first quarter. Vanguard Group Inc. now owns 9,093,712 shares of the company's stock worth $250,168,000 after purchasing an additional 746,263 shares during the period. ARK Investment Management LLC grew its position in Intellia Therapeutics by 5.5% during the second quarter. ARK Investment Management LLC now owns 11,595,789 shares of the company's stock worth $259,514,000 after buying an additional 606,507 shares in the last quarter. Federated Hermes Inc. grew its position in Intellia Therapeutics by 19.2% during the second quarter. Federated Hermes Inc. now owns 2,300,889 shares of the company's stock worth $51,494,000 after buying an additional 371,189 shares in the last quarter. Opaleye Management Inc. grew its position in Intellia Therapeutics by 157.6% during the first quarter. Opaleye Management Inc. now owns 255,000 shares of the company's stock worth $7,015,000 after buying an additional 156,000 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in Intellia Therapeutics by 8.1% during the second quarter. Dimensional Fund Advisors LP now owns 1,324,561 shares of the company's stock worth $29,648,000 after buying an additional 98,865 shares in the last quarter. Institutional investors own 88.77% of the company's stock.
Intellia Therapeutics Company Profile
(
Get Free Report)
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
See Also
Before you consider Intellia Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.
While Intellia Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
